Tag: Rare Disease

  • Daily Tech Digest: Google’s Gemini AI Chip, Xiaomi 18 Early Launch, Anthropic Rare Disease Research, and X Phishing Scams

    Daily Tech Digest: Google’s Gemini AI Chip, Xiaomi 18 Early Launch, Anthropic Rare Disease Research, and X Phishing Scams

    Today’s tech landscape is buzzing with major developments. Google’s upcoming Frozen v2 AI chip is designed to boost the efficiency of its Gemini model, with deployment potentially starting in 2028. Meanwhile, Xiaomi’s next flagship, the Xiaomi 18, may launch earlier than expected in India, signaling a strategic push in the competitive smartphone market. In healthcare AI, Anthropic is funding research into rare diseases, leveraging its AI capabilities to address underserved medical areas. On the security front, X (formerly Twitter) is facing a wave of phishing scams targeting users, raising concerns about platform safety. Additionally, the broader conversation around AI governance in healthcare continues to evolve, as regulators and companies work to balance innovation with patient privacy and ethical standards.

  • Pangaea Data and Sanofi Use AI to Detect Rare Disease Alpha-1 Antitrypsin Deficiency

    Pangaea Data and Sanofi Use AI to Detect Rare Disease Alpha-1 Antitrypsin Deficiency

    Pangaea Data, a provider of guideline-configured AI solutions, has partnered with Sanofi to deploy machine learning algorithms that analyze electronic health record (EHR) data. The collaboration aims to identify patients with Alpha-1 Antitrypsin Deficiency (AATD) earlier, addressing the chronic underdiagnosis of this rare genetic disorder across the United States.

    Research indicates that up to 90% of individuals with AATD remain undiagnosed, often waiting five to eight years for confirmation after symptoms appear. The AI platform processes real-time clinical data, including structured fields and unstructured physician notes, to flag patients who may need further evaluation without adding administrative burden.

    “We are pleased to support the deployment of innovative solutions like Pangaea’s platform that can help not only identify patients in need of evaluation earlier using real-time, real world data that remains securely within the health system, but also address workflow challenges,” said Lisa Sniderman King, Senior Director, Scientific Affairs and Diagnostics, US Medical at Sanofi.

    The technology integrates with existing EHR systems, scheduling tools, and communication platforms, delivering insights directly into clinical workflows. Population health dashboards further enable health system leaders to spot care gaps and ensure guideline adherence.

    While the initial focus is on AATD, both companies envision broader applications for respiratory and rare diseases such as severe asthma and COPD. Dr. Vibhor Gupta, CEO and Founder of Pangaea Data, commented, “We are excited to work with Sanofi beginning with AATD while advancing a broader vision for scalable, guideline-configured AI that can help scale earlier detection, screening and management across chronic and rare hard-to-diagnose conditions.”